Skip to content

Welcome to Discover Pharma! Today is : October 30, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Movers and Shakers

  • Biotech & Pharma Business,Pharmaceuticals and therapeutics

    Inizio appoints Ryan Quigley as new chief executive officer

    Inizio has appointed Ryan Quigley as its new chief executive [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Amorphical names Eden Ben CEO to drive regulatory strategy and expand nano-mineral therapeutics pipeline

    Amorphical has appointed Eden Ben as chief executive officer, as [...]

    May 5, 2026
  • Pharmaceuticals and therapeutics

    Genmab names Matt Kiely as UK general manager to spearhead commercial expansion

    Genmab has appointed Matt Kiely as general manager for the [...]

    September 7, 2025
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Strand Therapeutics appoints Jason Luke as chief medical officer

    Strand Therapeutics has appointed oncology researcher Jason Luke as its [...]

    May 5, 2026
Previous56

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Lab-grown human neuromuscular junctions advance MND drug discovery
    Categories: Research & Development, Therapeutic Areas
  • Olink assay correlates with ELISA for measuring endothelin-1
    Categories: Clinical & Regulatory, Research & Development
  • BridgeBio gets FDA Priority Review for oral infigratinib in achondroplasia
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top